Abstract:Chimeric antigen receptor T-cell (CAR-T) therapy has achieved good therapeutic efficacy in the treatment of hematological malignancies. In August 2017, Novartis Kymriah (CAR-T cells targeting CD19) was approved by the FDA, indicating the real entry of CAR-T cell therapy into clinical applications and making CAR-T cell therapy the most attractive technology in the field of tumor treatment. In October 2017, the FDA approved the world's second CAR-T cell therapy-Yescarta. The launch of these products has attracted wide attention to CAR-T cell therapy. CAR-T cell therapy has achieved significant effect in the treatment of tumors, however, CAR-T therapy also faces clinical problems, such as cytokine release syndrome (CRS), poor therapeutic efficacy in solid tumors, and high rates of tumor recurrence. At present, the side effects of CAR-T therapy have attracted a large amount of attention, which has resulted in investigations into strategy establishment. With a deepening understanding of CAR-T therapy and the continuous optimization of therapeutic regimens, its toxicity and side effects have been partially controlled. This study set out to analyze the problems in the clinical application of CAR-T therapy encountered in recent years and to introduce corresponding strategies, with the aim of providing a basis of reference for clinicians and scientists in the management of CAR-T therapy in clinical practice and in the CAR-T therapy research.

Clinical Application of CAR-T Cells in Treatment of Hematologic Malignancies

CAR‐T Therapy in Clinical Practice: Technical Advances and Current Challenges

[Progress in Clinical Studies of Chimeric Antigen Receptor Engineered T Cells for Treatment of Childhood Cancer].

[Advances in Immunotherapy of Hematological Malignancies by Using Chimeric Antigen Receptor-Modified Lymphocytes].

Progress on CAR-T Cell Therapy for Hematological Malignancies

Current Status and Problems of Chimeric Antigen Receptor T Cell Immunotherapy in Treatment of Hematological Malignancies

CAR-T Cell Therapy for Hematological Malignancies: History, Status and Promise

Challenges and optimal strategies of CAR T therapy for hematological malignancies.

Recent advances in CAR-T therapy for the treatment of acute myeloid leukemia

CAR-T Cell Therapy in Hematological Malignancies: Current Opportunities and Challenges

The application of CAR-T cell therapy in hematological malignancies: advantages and challenges

Advances in chimeric antigen receptor T cell therapy for treatment of hematological malignancies

Current progress in CAR-T cell therapy for tumor treatment

Generating advanced CAR-based therapy for hematological malignancies in clinical practice: targets to cell sources to combinational strategies

Strategies to optimize chimeric antigen receptor T-cell therapy in hematologic malignancies: Chinese experience

Progress in clinical application of chimeric antigen receptor-T cells for the refractory and relapsed B-cell leukemia

CAR T-cell Immunotherapy: a Powerful Weapon for Fighting Hematological B-cell Malignancies

Current Progress in CAR-T Cell Therapy for Hematological Malignancies

Recent progress in chimeric antigen receptor therapy for acute myeloid leukemia

Challenges and strategies of clinical application of CAR-T therapy in the treatment of tumors—a narrative review

Advances in CAR-T-cell therapy in T-cell malignancies